OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Given Consensus Recommendation of “Hold” by Analysts

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) has been assigned an average rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $6.3333.

OKYO has been the subject of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a report on Thursday, January 29th. Piper Sandler initiated coverage on shares of OKYO Pharma in a research report on Friday, February 20th. They set an “overweight” rating and a $7.00 target price for the company. Finally, B. Riley Financial assumed coverage on shares of OKYO Pharma in a report on Monday, December 8th. They issued a “buy” rating and a $5.00 price target on the stock.

Institutional Trading of OKYO Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in OKYO Pharma in the third quarter valued at approximately $31,000. XTX Topco Ltd purchased a new position in shares of OKYO Pharma during the 4th quarter valued at approximately $36,000. Finally, Renaissance Technologies LLC increased its holdings in shares of OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after purchasing an additional 96,800 shares in the last quarter. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Stock Up 1.2%

Shares of OKYO opened at $1.72 on Friday. The stock has a 50-day moving average of $2.10 and a two-hundred day moving average of $2.19. OKYO Pharma has a one year low of $1.03 and a one year high of $3.35.

OKYO Pharma (NASDAQ:OKYO) last announced its quarterly earnings data on Friday, January 30th. The company reported ($2.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($2.21). On average, equities analysts expect that OKYO Pharma will post -0.17 earnings per share for the current year.

About OKYO Pharma

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.